|

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

RECRUITINGPhase 2Sponsored by University Health Network, Toronto
Actively Recruiting
PhasePhase 2
SponsorUniversity Health Network, Toronto
Started2025-07-08
Est. completion2030-06
Eligibility
Age18 Years – 100 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06927635

Summary

This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).

Eligibility

Age: 18 Years – 100 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Age \>18 years
* Able to provide informed consent
* Histologic diagnosis of prostate adenocarcinoma
* Castrate Resistance Prostate Cancer
* Radiographic evidence of \<10 sites of extra-cranial OP metastatic lesions
* Receiving any line of ST for \>3 months
* All sites of OP disease are amenable to and can be safely treated with SBRT
* ECOG performance status 0-3

Exclusion Criteria:

* Evidence of spinal cord compression
* Contraindication to radiotherapy

Conditions3

CancerCastrate Resistance Prostate CancerOligoProgressive Metastatic Disease

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.